Express Scripts Holding Company (NASDAQ: ESRX) shares fell following news that Sen. Ron Wyden proposed legislation requiring drug middlemen from disclosing secret discounts they receive from manufacturers. The company did express to Benzinga it's working with Sen. Wyden, acknowledging the risks the new legislation may present.
Following the news, alongside the threat that the company will lose its contract with healthcare provider Anthem Inc (NYSE: ANTM), analysts at Wells Fargo downgraded the stock to Underperform from Market Perform.
“We are downgrading shares of ESRX, reflecting our view that the shares do not fully reflect the 20-40% earnings risk related to repricing of or losing the ANTM contract, Express’ largest customer,” Wells Fargo said.
“We see risk of market share losses stemming from Express’ PBM model given our view that its stand-alone model does not position ESRX well to compete effectively against CVS Caremark’s broader dispending venue model and UNH OptumRx’s integrated medical model,” Wells Fargo said.
Wells Fargo has lowered its valuation range on the company to $52-56, down from $79-85, although left its EPS estimates unchanged. Given the considerable risks to Express Scripts’ business model amid a constantly changing healthcare industry, the company could see more downgrades in the near term.
Express Scripts Confirms It's Working With Sen. Wyden's Bill
Stocks To Watch As CBO Expected To Release Score For GOP Healthcare Bill
Latest Ratings for ESRX
|Mar 2017||Wells Fargo||Downgrades||Market Perform||Underperform|
|Nov 2016||Deutsche Bank||Upgrades||Sell||Hold|
|Oct 2016||UBS||Initiates Coverage on||Neutral|
View More Analyst Ratings for ESRX
View the Latest Analyst Ratings
See more from Benzinga
- The Curious Case Of Lavar, Lonzo, LiAngelo And LaMelo Ball
- Insureon Looks To Serve The 75% Of Small Businesses That Are Underinsured
- Wells Fargo Sees FedEx More Likely To Deliver Gains Than UPS
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.